Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 756265, 6 pages
http://dx.doi.org/10.5402/2011/756265
Research Article

Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer

1Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, 215-4, Gongneung-dong, Nowon-gu, Seoul 139-706, Republic of Korea
2Department of Radiology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul 139-706, Republic of Korea
3Department of Laboratory Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul 139-706, Republic of Korea
4Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul 139-706, Republic of Korea

Received 15 February 2011; Accepted 24 March 2011

Academic Editors: B. Fang and L. Mutti

Copyright © 2011 Im Il Na et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We performed this retrospective study to assess the association of epidermal growth factor receptor (EGFR) with metastatic presentations in advanced non-small cell lung cancer (NSCLC). The data from 125 patients with stage III or IV NSCLC were analyzed. We detected EGFR mutations in 36 NSCLC patients. EGFR mutations were predominant in never-smokers ( 𝑃 < . 0 0 1 ) , patients with adenocarcinomas ( 𝑃 < . 0 0 1 ) , and female patients ( 𝑃 < . 0 0 1 ) . When the metastatic sites were analyzed, pleural metastases were associated with a high incidence of EGFR mutations ( 𝑃 = . 0 2 8 ) . Particularly, pleural metastases with minimal effusion (PMME) were associated with EGFR mutational status ( 𝑃 = . 0 0 1 ) . Patients with N3 lesions were less likely to harbor EGFR mutations ( 𝑃 = . 0 3 3 ) . On multivariate analysis, N3 lesions ( 𝑃 = . 0 1 7 ) and PMME ( 𝑃 < . 0 0 1 ) remained significant factors for EGFR mutations. EGFR mutations may be associated with different presentations of pleural and N3 nodal metastases.